Última actualización :
19/11/2024
Antibiótico   Netilmicin sulfate  
Inyectables
Aerosol
Estabilidad en solucion Estabilidad en mezcla Factores que influyen sobre la estabilidad Compatibilidades método de inyección Bibliografía pdf
   Estructura química  

Nombre comercial   Nombre comercial     

Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.

Bactob India
Beltob India
Bramicil Italia
Brulamycin Hungría
Eltol India
Fytobra India
Gernebcin Alemania
Komitub India
Nebcin Arabia Saudita, Australia, Egipto, Emiratos Árabes Unidos, Gran Bretaña, Grecia, Nueva Zelanda
Nebcina Dinamarca, Marruecos, Noruega, Suecia
Nebcine Marruecos
Nebicina Italia
Netilyn Finlandia, Suecia
Netromicina Portugal
Netromicine Francia
Netromycine Grecia, Polonia, ruso, Turquía
Nettacin Italia
Obracin Bélgica, Luxemburgo, Países Bajos, Suiza
Tobra Alemania
Tobra Alex Egipto
Tobra Day Nueva Zelanda
Tobra Gobens España
Tobracin Egipto
Tobradistin España
Tobramicina España, Italia, Portugal, Venezuela
Tobramina Brasil
Tobramycin Alemania, Arabia Saudita, Australia, Canadá, Estados Unidos de América, Gran Bretaña, Irlanda, Noruega
Tobramycine Bélgica, Canadá, Luxemburgo, Países Bajos
Tobrasix Austria
Tobrazid Alemania
Tomycin Finlandia
Zetamicin Italia
Bibliografía   Inyectables   Bibliografía : Netilmicin sulfate  
Tipo Publicación
3 periódico Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59 periódico Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
84 periódico Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 periódico Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 periódico Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 periódico Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 periódico Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 periódico Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 periódico Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
289 periódico Jim LK.
Physical and chemical compatibility of intravenous ciprofloxacin with other drugs.
Ann Pharmacotherapy 1993 ; 27: 704-707.
299 periódico Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 periódico Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 periódico Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 periódico Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
335 periódico Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
367 periódico Thompson DF, Allen LV, Desai SR, Rao PS.
Compatibility of furosemide with aminoglycoside admixtures.
Am J Hosp Pharm 1985 ; 42: 116-119.
421 periódico Foley PT, Bosso JA, Bair JN, Townsend RJ.
Compatibility of clindamycin phosphate with cefotaxim sodium or netilmicin sulfate in small-volume admixtures.
Am J Hosp Pharm 1985 ; 42: 839-843.
492 periódico Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
905 periódico Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 periódico Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
958 periódico Vervloet E, Lammers J, Tan LSL, Van Mourik CH, Rots M.
Netilmicin sulfate stability in combinaison with metronidazole or ranitidine hydrochloride in NaCl 0.9% infusion.
Ann Pharmacotherapy 1990 ; 24: 440-442.
999 periódico Watson D.
Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution.
JPEN 1985 ; 9: 220-224.
1022 periódico Hutchinson SMW.
Heparin and aminoglycosides instability.
Drug Intell Clin Pharm 1986 ; 20: 886.
1035 periódico Bisaillon S, Sarrazin R.
Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion.
J Parenter Sci Technol 1983 ; 37: 129-132.
1200 periódico Chaudry IA, Bruey KP, Hurlburt LE, Oden EM.
Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives.
Am J Hosp Pharm 1981 ; 38: 1737-1742.
1236 periódico Kuhn RJ, Nahata MC.
Stability of netilmicin sulfate in admixtures with calcium gluconate and aminophylline.
Am J Hosp Pharm 1986 ; 43: 1241-1242.
1410 periódico Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 periódico Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 periódico Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1754 periódico Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1925 periódico Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1929 periódico Rigge DC, Jones MF.
Shelf lives of aseptically prepared medicines - stability of netilmicin injection in polypropylene syringes.
J Pharm Biomed Anal 2004 ; 35: 1251-1256.
2296 Laboratorio Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017
3522 Laboratorio Flucloxacillin - Summary of Product Characteristics.
Actavis 2013
3523 Laboratorio Ceftriaxone (Rocephin®) - Summary of Product Characteristics.
Roche 2018
3526 Laboratorio Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010
3527 Laboratorio Amoxicillin (Amoxil®) – Summary of Product Characteristics
Glaxo Smith Kline 2018
3540 Laboratorio Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3543 Laboratorio Ceftazidime – Summary of Product Characteristics
Wockhardt 2013
3544 Laboratorio Cefoperazone (Cefobid®) - Summary of Product Characteristics
Pfizer 2006
3545 Laboratorio Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit
Mylan SAS 2009
3546 Laboratorio Cefamandole Flavelab - Résumé des caractéristiques du produit
Panpharma SA 2007
3548 Laboratorio Cefepime (Maxipime®) - Summary of Product caracteristics.
Bristol Myers Squibb 2007
3578 Laboratorio Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3586 Laboratorio Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit
Actavis France 2010
3587 Laboratorio Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics
GlaxoSmithKline 2014
3594 Laboratorio Metronidazole (Flagyl®) - Summary of Product Characteristics
Zentiva 2013
3644 Laboratorio Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3656 Laboratorio Teicoplanine (Targocid®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2014
3674 Laboratorio Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3687 Laboratorio Cefuroxime sodium - Summary of Product Characteristics
Stravencon 2013
3883 Laboratorio Ceftazidime - Résumé des caractéristiques du produit
Arrow 2016

  Mentions Légales